Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research
Summary
The novel technology enables rapid prototyping of mRNA candidates to test diverse combinations of CAP analogs, chemistry modifications, and sequence designs for client discovery programs. “Officinae Bio’s unique approach to sequence design brings a cutting-edge advantage to our Nucleic Acid Production business,” said Trey Martin, CEO of Maravai LifeSciences. We are excited to welcome their exceptionally talented team to Maravai to help drive process and manufacturing innovation forward together.” Justin Barbosa, GM and Vice President of TriLink Discovery, added, “Officinae Bio’s ability to marry leading science with AI-enabled methodologies provides a one-of-a-kind sequence design experience for customers. Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Our Mercury RNA platform generates libraries of precisely engineered UTRs (untranslated regions), optimizing efficacy and safety through enhanced translation and tissue-specificity This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S.